• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向 CD47 和 PD-L1 的轻链驱动双特异性抗体的结构分析。

Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1.

机构信息

Light Chain Bioscience - Novimmune SA, Plan-les-Ouates, Switzerland.

SARomics Biostructures AB, Lund, Sweden.

出版信息

MAbs. 2024 Jan-Dec;16(1):2362432. doi: 10.1080/19420862.2024.2362432. Epub 2024 Jun 7.

DOI:10.1080/19420862.2024.2362432
PMID:38849989
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11164222/
Abstract

In contrast to natural antibodies that rely mainly on the heavy chain to establish contacts with their cognate antigen, we have developed a bispecific antibody format in which the light chain (LC) drives antigen binding and specificity. To better understand epitope-paratope interactions in this context, we determined the X-ray crystallographic structures of an antigen binding fragment (Fab) in complex with human CD47 and another Fab in complex with human PD-L1. These Fabs contain a κ-LC and a λ-LC, respectively, which are paired with an identical heavy chain (HC). The structural analysis of these complexes revealed the dominant contribution of the LCs to antigen binding, but also that the common HC provides some contacts in both CD47 and PD-L1 Fab complexes. The anti-CD47 Fab was affinity optimized by diversifying complementary-determining regions of the LC followed by phage display selections. Using homology modeling, the contributions of the amino acid modification to the affinity increase were analyzed. Our results demonstrate that, despite a less prominent role in natural antibodies, the LC can mediate high affinity binding to different antigens and neutralize their biological function. Importantly, Fabs containing a common variable heavy (VH) domain enable the generation of bispecific antibodies retaining a truly native structure, maximizing their therapeutic potential.

摘要

与主要依赖重链与相应抗原建立联系的天然抗体不同,我们开发了一种双特异性抗体形式,其中轻链(LC)驱动抗原结合和特异性。为了更好地理解这种情况下的表位-抗体互补决定区相互作用,我们确定了与人类 CD47 结合的抗原结合片段(Fab)和与人类 PD-L1 结合的另一个 Fab 的 X 射线晶体结构。这些 Fab 分别包含 κ-LC 和 λ-LC,它们与相同的重链(HC)配对。这些复合物的结构分析表明,LC 对抗原结合的贡献占主导地位,但共同的 HC 也在 CD47 和 PD-L1 Fab 复合物中提供了一些接触。通过对 LC 的互补决定区进行多样化,然后进行噬菌体展示选择,对抗 CD47 Fab 进行了亲和力优化。使用同源建模分析了氨基酸修饰对亲和力增加的贡献。我们的结果表明,尽管在天然抗体中的作用不那么突出,但 LC 可以介导与不同抗原的高亲和力结合,并中和它们的生物学功能。重要的是,含有共同可变重链(VH)结构域的 Fab 能够产生保留真正天然结构的双特异性抗体,最大限度地发挥其治疗潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a92/11164222/0a0a0dac503f/KMAB_A_2362432_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a92/11164222/d5844a774ecb/KMAB_A_2362432_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a92/11164222/92b0e8b98c88/KMAB_A_2362432_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a92/11164222/9dcf875ae9c1/KMAB_A_2362432_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a92/11164222/b56a8d660308/KMAB_A_2362432_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a92/11164222/0a0a0dac503f/KMAB_A_2362432_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a92/11164222/d5844a774ecb/KMAB_A_2362432_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a92/11164222/92b0e8b98c88/KMAB_A_2362432_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a92/11164222/9dcf875ae9c1/KMAB_A_2362432_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a92/11164222/b56a8d660308/KMAB_A_2362432_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a92/11164222/0a0a0dac503f/KMAB_A_2362432_F0005_OC.jpg

相似文献

1
Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1.靶向 CD47 和 PD-L1 的轻链驱动双特异性抗体的结构分析。
MAbs. 2024 Jan-Dec;16(1):2362432. doi: 10.1080/19420862.2024.2362432. Epub 2024 Jun 7.
2
EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies.EFab 结构域取代作为双特异性抗体轻链配对问题的解决方案。
MAbs. 2018 Nov-Dec;10(8):1248-1259. doi: 10.1080/19420862.2018.1519631. Epub 2018 Sep 20.
3
Comparing domain interactions within antibody Fabs with kappa and lambda light chains.比较抗体Fabs中κ链和λ链的结构域相互作用。
MAbs. 2016 Oct;8(7):1276-1285. doi: 10.1080/19420862.2016.1214785. Epub 2016 Jul 25.
4
The eIg technology to generate Ig-like bispecific antibodies.利用 eIg 技术生成 Ig 样双特异性抗体。
MAbs. 2022 Jan-Dec;14(1):2063043. doi: 10.1080/19420862.2022.2063043.
5
Novel CH1:CL interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies.新型CH1:CL界面可增强异二聚体双特异性抗体中轻链的正确配对。
Protein Eng Des Sel. 2017 Sep 1;30(9):685-696. doi: 10.1093/protein/gzx044.
6
Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of 'Almost Natural' Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection.双管齐下:牛科超长 CDR-H3 互补决定区使工程化“近乎天然”的通用轻链双特异性抗体用于效应细胞重定向成为可能。
Front Immunol. 2022 Jan 11;12:801368. doi: 10.3389/fimmu.2021.801368. eCollection 2021.
7
Functional humanization of an anti-CD16 Fab fragment: obstacles of switching from murine {lambda} to human {lambda} or {kappa} light chains.抗CD16 Fab片段的功能性人源化:从小鼠λ链转换为人λ链或κ链的障碍。
Protein Eng Des Sel. 2009 Mar;22(3):175-88. doi: 10.1093/protein/gzn066. Epub 2008 Nov 19.
8
Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.用于在双特异性抗体中共同表达Fab样部分的IgG/TCR嵌合体的蛋白质设计。
MAbs. 2015;7(2):364-76. doi: 10.1080/19420862.2015.1007826.
9
Selective CD47 targeting with a bispecific antibody.用双特异性抗体选择性靶向CD47。
Cancer Immunol Immunother. 2021 Apr;70(4):1161-1162. doi: 10.1007/s00262-020-02812-4. Epub 2021 Jan 2.
10
"BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.“双特异性抗体”:在瞬时转染的哺乳动物细胞中生产IgG形式的双特异性抗体
Methods Mol Biol. 2019;1904:431-454. doi: 10.1007/978-1-4939-8958-4_22.

引用本文的文献

1
NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control.NI-3201是一种双特异性抗体,可介导T细胞上依赖程序性死亡受体配体1(PD-L1)的共刺激信号,从而增强对肿瘤的控制。
Cancer Immunol Res. 2025 Mar 4;13(3):365-383. doi: 10.1158/2326-6066.CIR-24-0298.

本文引用的文献

1
Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody.利用新型 CEACAM5xCD47κλ 双特异性抗体 NILK-2401 靶向 CEACAM5 阳性实体瘤。
Front Immunol. 2024 Apr 24;15:1378813. doi: 10.3389/fimmu.2024.1378813. eCollection 2024.
2
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers.开发和鉴定 NILK-2301,一种新型的 CEACAM5xCD3 κλ 双特异性抗体,用于治疗表达 CEACAM5 的癌症的免疫疗法。
J Hematol Oncol. 2023 Dec 12;16(1):117. doi: 10.1186/s13045-023-01516-3.
3
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies.
揭示人类免疫系统的奥秘:功能性抗体互补决定区复杂性的全面特征分析。
MAbs. 2023 Jan-Dec;15(1):2268255. doi: 10.1080/19420862.2023.2268255. Epub 2023 Oct 24.
4
Polyspecificity - An emerging trend in the development of clinical antibodies.多特异性 - 临床抗体开发的新兴趋势。
Mol Immunol. 2023 Mar;155:175-183. doi: 10.1016/j.molimm.2023.02.005. Epub 2023 Feb 22.
5
Antibodies to watch in 2023.2023 年值得关注的抗体药物
MAbs. 2023 Jan-Dec;15(1):2153410. doi: 10.1080/19420862.2022.2153410.
6
Antibody-Antigen Binding Interface Analysis in the Big Data Era.大数据时代的抗体-抗原结合界面分析
Front Mol Biosci. 2022 Jul 14;9:945808. doi: 10.3389/fmolb.2022.945808. eCollection 2022.
7
CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies.基于 CD47-SIRPα 阻断的免疫疗法:当前和未来的治疗策略。
Clin Transl Med. 2022 Aug;12(8):e943. doi: 10.1002/ctm2.943.
8
CD47/SIRPα axis: bridging innate and adaptive immunity.CD47/SIRPα 轴:连接先天免疫和适应性免疫。
J Immunother Cancer. 2022 Jul;10(7). doi: 10.1136/jitc-2022-004589.
9
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model.CD47xCD19双特异性抗体在B细胞淋巴瘤异种移植模型中触发先天性免疫效应细胞的募集和激活。
Exp Hematol Oncol. 2022 May 10;11(1):26. doi: 10.1186/s40164-022-00279-w.
10
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology.基于双特异性抗体的免疫疗法在肿瘤学中的免疫原性评估。
J Immunother Cancer. 2022 Apr;10(4). doi: 10.1136/jitc-2021-004225.